Oligonucleotide Synthesis Market DROT, Analysis & Forecast Till 2035
The contract manufacturing market for oligonucleotides is highly fragmented, featuring the presence of established companies, as well as emerging start-ups. Close to 45% of the companies engaged in this domain are headquartered in North America; of these, majority are mid-sized players (14%), followed by large and small firms (13% each). Majority (72) of the companies synthesize RNA oligonucleotides, such as small interfering RNA (siRNA) (49), micro-RNA (miRNA) (25) and Decoy RNA (8). This can be attributed to the various advantages offered by RNA oligonucleotides, including high specificity, gene expression regulation and relative safety. In addition, close to 45% of the synthesis providers offer services across all scales of operations. Further, close to 90% of the players offer purification services.
Read More; https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/304.html
During our research, we came across 64 partnerships that have been inked by various stakeholders engaged in the oligonucleotide synthesis market, during the period 2014-2023 (till September). It is worth noting that in 2023, acquisitions (34%) emerged as the most popular type of partnership model adopted by players engaged in the oligonucleotide synthesis domain. This can be attributed to the incessant efforts of players to further advance the development of their oligonucleotide products. This is followed by manufacturing agreements (16%) and service alliances (14%).
In order to accommodate their growing businesses, contract manufacturers are heavily investing in either expanding their existing facilities / capabilities or construct / acquire new facilities in other geographies. During our research, we identified close to 60 expansion initiatives that have been undertaken in the oligonucleotide synthesis industry, during the period 2015-2023. As can be observed in the figure, majority of the expansion initiatives undertaken by the oligonucleotide synthesis providers were reported during the period 2021. This can be attributed to the indubitably rising demand for oligonucleotides in the COVID-19 pandemic.
Owing to several factors, including globalization and introduction of political and regulatory reforms, advanced contract manufacturing services for oligonucleotides are no longer confined to the developed geographies alone. Currently, several players in emerging geographies, such as those based in China, India, Asia-Pacific and Latin America, offer high quality contract manufacturing services for oligonucleotides, along with providing lucrative cost benefits.
Browse More Related:
Medical Polymers Market
https://www.rootsanalysis.com/reports/medical-polymers-market.html
Modular Construction Market
https://www.rootsanalysis.com/reports/modular-manufacturing-market/178.html
Nutrigenomics Market
https://www.rootsanalysis.com/reports/nutrigenomics-market.html
Given the growing complexity of APIs, the demand for oligonucleotides has upsurged; by 2035, it is anticipated to reach around 2,200 kilograms, across clinical and commercial scales
As can be observed in the figure, in 2024, the global demand for oligonucleotides is estimated to grow at an annualized growth rate (CAGR) of 17%. The significant upsurge in the overall demand for such products can be attributed to the fact that patents for some of the drugs are likely to expire in the coming few years, and consequently, several biosimilars are anticipated to be approved in the mid-long term, enabling an exponential increase in the overall demand for oligonucleotides. Further, the rising in the clinical demand can be attributed to the rising number of patients enrolled in clinical trials for evaluating oligonucleotides. Increase in the number can be attributed to the ability of these oligonucleotides to treat various indications, such as metabolic disorders and oncological disorders.
About roots analysis
Roots analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including fortune 500 companies, start-ups, academia, venture catalysts, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organizations worldwide.
All our analysts are trained to produce high-quality research work. They are continuously mentored by senior experts to present an original, unbiased and informed perspective on pressing issues in the industry. On any particular subject, we bring together the best available resources to ensure highest quality in all our reports.